


-115-
CLAIMS

What is claimed is:

1. A compound of the formula:



in which;

- a) X^1 is represented by cyano, halogen or haloalkyl,
- b) R^1 and R^2 are each independently represented by hydrogen or (C_1-C_6) alkyl, optionally substituted,
- c) Alk^1 is represented by a C_1-C_2 linear alkylene group, in which up to two hydrogen atoms are optionally replaced by a substituent selected from the group consisting of C_1-C_6 alkyl optionally substituted, halogen, hydroxy, thiol, and cyano,
- d) n is represented by the integer 0 or 1,
- e) Y is represented by NX^2X^3 or $O-X^3$,
- f) X^2 is represented by hydrogen or (C_1-C_6) alkyl optionally substituted,
- g) X^3 is represented by
 - i. hydrogen,
 - ii. (C_1-C_{12}) alkyl, optionally substituted,
 - iii. (C_2-C_{12}) alkenyl, optionally substituted,
 - iv. (C_2-C_{12}) alkynyl, optionally substituted,
 - v. (C_3-C_{10}) cycloalkyl, optionally substituted,
 - vi. (C_6-C_{10}) cycloalkyl/ (C_1-C_6) alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
 - vii. (C_6-C_{10}) aryl, optionally substituted,
 - viii. (C_6-C_{10}) aryl/ (C_1-C_6) alkyl, in which the alkyl and aryl moieties may each be optionally substituted,

-116-

- ix. $-(\text{CH}_2)_q-(\text{Alk}^2)_q-\text{C}(\text{O})\text{R}^3$, in which Alk^2 is represented by a (C_1-C_8) linear alkylene group, in which up to eight hydrogen atoms may optionally be replaced by a substituent, selected from the group consisting of (C_1-C_8) alkyl optionally substituted, (C_1-C_8) alkoxy, halogen, hydroxy, thiol, cyano, and NR^8R^9 in which R^8 and R^9 are each independently represented by hydrogen or (C_1-C_6) alkyl, q is the integer 0 or 1, R^3 is represented by hydrogen, $(\text{C}_1-\text{C}_{12})$ alkyl, $(\text{C}_6-\text{C}_{10})$ aryl, or $(\text{C}_6-\text{C}_{10})$ aryl (C_1-C_6) alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
- x. $-(\text{CH}_2)_q-(\text{Alk}^2)_q-\text{C}(\text{O})-\text{O}-\text{R}^4$, in which Alk^2 and q are as defined above, and R^4 is represented by hydrogen, $(\text{C}_1-\text{C}_{12})$ alkyl, $(\text{C}_6-\text{C}_{10})$ aryl, or $(\text{C}_6-\text{C}_{10})$ aryl (C_1-C_6) alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xi. $-(\text{CH}_2)_q-(\text{Alk}^2)_q-\text{C}(\text{O})-\text{NR}^5\text{R}^6$ in which Alk^2 and q are as described above, and R^5 and R^6 are each independently represented by hydrogen, $(\text{C}_1-\text{C}_{12})$ alkyl, $(\text{C}_6-\text{C}_{10})$ aryl, or $(\text{C}_6-\text{C}_{10})$ aryl (C_1-C_6) alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xii. $-(\text{CH}_2)_q-(\text{Alk}^2)_q-\text{Y}-\text{R}^7$, in which Alk^2 and q are as defined above, Y is O or S, and R^7 is selected from the group consisting of hydrogen, $(\text{C}_1-\text{C}_{12})$ alkyl, $(\text{C}_6-\text{C}_{10})$ aryl, or $(\text{C}_6-\text{C}_{10})$ aryl (C_1-C_6) alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xiii. heteroaryl, optionally substituted,
- xiv. heteroaryl (C_1-C_6) alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted,
- xv. heterocyclic, optionally substituted,
- xvi. heterocyclic (C_1-C_6) alkyl, in which the alkyl

-117-

and heterocyclic moieties may each be substituted, or,

h) for those compounds in which Y is N, X² and X³, along with the adjacent nitrogen atom, may form a heterocyclic ring, which may optionally be substituted, or a salt, solvate, or prodrug thereof.

2. A compound according to claim 1 in which one of R¹ or R² is hydrogen and the other of R¹ or R² is selected from the group consisting of isobutyl, propyl, n-butyl, isopropyl, and ethyl.
3. A compound according to claim 1 or 2 in which n is 0.
4. A compound according to claim 1, 2, or 3 in which X¹ is trifluoromethyl and is located at the 3-position of the phenyl ring.
5. A compound according to claim 1, 2, 3, or 4 in which Y is NX²X³.
6. A compound according to claim 5 in which X² is hydrogen.
7. A compound according to claim 6 in which X³ is represented by a substituent selected from the group consisting of (C₁-C₁₂)alkyl, (C₃-C₁₀)cycloalkyl, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₆)alkyl, heteroaryl, (C₁-C₆)alkyl, and heterocyclic(C₁-C₆)alkyl.
8. A compound according to claim 1, 2, 3, or 4 in which Y is OX³.
9. A compound according to anyone of claims 1-8 in which X¹ is represented by halogen or haloalkyl.
10. Use of a compound according to anyone of claims 1-9 as a medicine.
11. Use of a compound according to anyone of claims 1-9 in the manufacture of a medicament for inhibiting activation of the androgen receptor

-118-

12. Use of a compound according to anyone of claims 1-9 in the manufacture of a medicament for the alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia.
13. A pharmaceutical composition comprising a compound according to anyone of claims 1-9 in admixture with 1, or more, pharmaceutically acceptable excipients.
14. A topical pharmaceutical formulation comprising a compound according to anyone of claims 1-9 in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application.
15. An article of manufacture comprising a compound according to anyone of claims 1-9 packaged for retail distribution, which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.